Brain

Press Release Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics

PRESS RELEASE, July 07, 2026 – 08:00 CDT Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology...

Beckman Coulter Diagnostics Expands Alzheimer’s Portfolio with CE-Marked p-Tau217 Blood Test and New High-Specificity Research Assay

CE-marked Access p-Tau217 blood test designed to support clinical evaluation of amyloid pathology in patients with signs and symptoms of...

EnteroBiotix Announces First Patient Dosed in Phase 2b RISE Study of EBX-102-02 in Irritable Bowel Syndrome with Constipation

GLASGOW, Scotland, July 07, 2026 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EnteroBiotix”), a clinical-stage biopharmaceutical company developing orally delivered full-spectrum microbiome...

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with Once-Daily Dosing Potential MIAMI, FL /...

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed...

There Is No Place Like ALYZE: Why Health Experts Say Utah’s New Integrated Wellness Club Is in a Category of Its Own

Combining a CLIA-certified on-site laboratory, functional medicine, luxury fitness, precision medicine, full recovery services, and aesthetic wellness under one roof,...

Remepy Publishes New Evidence Showing its Hybrid Drug, Hybridopa™, Effect on Structural Connectivity in the Brain of Parkinson’s Patients Associated with Improved Clinical Outcome

New npj Parkinson's Disease publication, building on the previously reported Hybridopa™ Phase IIa results, demonstrates for the first time, that...

Oxford-Harrington Rare Disease Centre Strengthens Rare Childhood Cancer Programme Through Appointment of New Little Princess Trust Professor of Paediatric Oncology

Professor Isidro Cortés-Ciriano, an internationally recognised scientist with extensive experience in childhood cancer research, will accelerate Oxford-Harrington’s mission to translate...

Magnetic Resonance Imaging (MRI) Market to Reach USD 10.2 Billion by 2036 as AI Reconstruction and Low-Helium Systems Improve Imaging Efficiency | FMI

NEWARK, Del., June 30, 2026 /PRNewswire/ -- The global Magnetic Resonance Imaging (MRI) Market, according to Future Market Insights, is...

ITM, Helmholtz Munich and the University of Münster Announce Updated Preliminary Phase 1 Data with ITM-31 in Glioblastoma Patients

Patient enrollment has been completed; all enrolled patients remain aliveData presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual...

Zambon and Amneal Announce Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time...

error: Content is protected !!